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Abstract
Background: The necessity of a venous blood collection in all dengue diagnostic assays and the high cost of tests that are
available for testing during the viraemic period hinder early detection of dengue cases and thus could delay cluster
management. This study reports the utility of saliva in an assay that detects dengue virus (DENV)–specific immunoglobulin
A (Ig A) early in the phase of a dengue infection.
Methods and Findings: Using an antigen capture anti-DENV IgA (ACA) ELISA technique, we tested saliva samples collected
from dengue-confirmed patients. The sensitivity within 3 days from fever onset was over 36% in primary dengue infections.
The performance is markedly better in secondary infections, with 100% sensitivity reported in saliva samples from day 1
after fever onset. Serum and salivary IgA levels showed good correlation (Pearson’s r=0.69, p,0.001). Specificity was found
to be 97%.
Conclusion: Our findings suggest that this technique would be very useful in dengue endemic regions, where the
majority of dengue cases are secondary. The ACA-ELISA is easy to perform, cost effective, and especially useful in
laboratories without sophisticated equipment. Our findings established the usefulness and reliability of saliva for early
dengue diagnosis.
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Introduction
Dengue is one of the most prevalent mosquito-borne diseases in
humans. This disease is best controlled by regular Aedes source
reduction activities. However, total eradication of Aedes in a
densely populated urban area where the vector has established
itself is a daunting task. Dengue control must include prompt
control response to dengue clusters, and early and reliable
diagnosis of cases is critical to this effort, which aims to halt the
DENV transmission. There has been progress in recent years in
the development of dengue diagnostic tools, resulting in the
availability of suitable tests for each stage of the disease.
Specific detection of dengue viral ribonucleic acid (RNA) using
real-time reverse transcription (RT) polymerase chain reaction
(PCR) is widely utilized to diagnose and serotype dengue infections
in the early phase of the disease [1–7]. These techniques, while
rapid and effective in providing early dengue diagnosis, are costly
and require trained personnel to perform. It is thus only currently
available in a limited number of clinical laboratories. The more
recent development of DENV non-structural protein 1 (NS1)
antigen detection in the Enzyme-linked immunosorbant assay
(ELISA) and rapid lateral flow platform has offered clinical
laboratories an effective tool for early diagnosis during the febrile
phase of the disease [8–13].
The detection of anti-DENV immunoglobulin M (IgM) is the
most widely used serological assay in dengue diagnosis [14–21].
However, anti-DENV IgM is usually detected 5 to 6 d after the
onset of fever and thus could result in a delay in diagnosis.
Moreover, it can persist for more than 8 mo [20,22,23], and in
dengue-endemic countries such as Singapore, the detection of IgM
in a febrile patient does not necessarily indicate an acute dengue
infection. The requirement for analysis of paired samples collected
at least 7 d apart, for definitive diagnosis, could delay intervention
efforts.
Unfortunately, the necessity of a venous blood collection in all
available dengue diagnostic assays and the high cost of the tests
that are available for the viraemic period hinder the early
detection of cases and clusters. Phlebotomy in needlephobic febrile
individuals, especially children, can be challenging, and the
tendency to forgo a dengue blood test is high.
We have therefore worked toward saliva-based techniques that
could address the early phase of the disease. Saliva is known to be
rich in IgA, the concentration of which is 100 times greater than
that of IgM and 14 times greater than IgG, and should thus serve
as a good target for early diagnosis [24]. Usage of salivary IgG for
diagnosis and epidemiological studies has been described before
[24–26]. The use of serum anti-DENV IgA as a diagnostic marker
has previously been explored. Groen et al. [27] described the
simultaneous increase of DENV-specific IgA and IgM in dengue
patients and reported that IgA was short-lived compared to IgM
[27]. An antibody-capture IgA (AAC) ELISA was used. Using the
same technique, subsequent studies showed that anti-DENV IgA
typically appeared after IgM did and was thus not suitable for
dengue diagnostics [15,23,28]. The use of salivary IgA for disease
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Virus, Hepatitis A and B, Measles, Mumps, and Rubella [29–33].
In this prospective study, we developed a protocol that allows
saliva to be used for anti-DENV IgA detection. The technique,
antigen-capture anti-DENV IgA (ACA)-ELISA, not only in-
creased the sensitivity of DENV-specific IgA detection, it also
reduced the total test time to 90 min, when compared with a
previously published IgA assay.
Materials and Methods
Samples for Detection of Anti-DENV IgA
The Environmental Health Institute (EHI) is a national public
health laboratory that functions as a licensed diagnostic laboratory,
with an ISO9001 accreditation, as well as a research laboratory.
Three suites of characterized samples, collected in Singapore,
were used in this study. WHO criteria for dengue confirmation
was adhered to for the determination of dengue status in the
following samples: The first (A) comprised saliva and sera collected
from 10 healthy volunteers as well as dengue-confirmed patients
for optimization of the protocol. The sera from healthy volunteers
were previously confirmed to be dengue negative via DENV RT-
PCR and PanBio IgM Capture ELISA, and their negative anti-
DENV IgA status was ascertained in both saliva and sera using a
previously reported DENV Antibody Capture IgA ELISA (AAC-
ELISA) [23]. The samples from dengue-confirmed patients
consisted of saliva and sera sequentially collected from five
patients during the acute phase of their disease. The dengue status
of these patients was confirmed by RT-PCR on sera collected in
the first 72 h and subsequent sero-conversion as demonstrated by
IgM assays. These five sets of saliva and sera samples were also
previously confirmed to be DENV IgA positive in AAC-ELISA.
Samples in this suite were used as reference samples to establish
the ACA-ELISA.
The second suite of samples (B), for evaluation of the newly
developed ACA-ELISA protocol, consisted of saliva and sera
obtained from 69 DENV-PCR-confirmed patients through three
consecutive collections. The first collection was within 72 h after
fever onset, second collection around 3 d after first collection, and
third collection within 21 d after fever onset. IgM tests, performed
on all three collections of each patient, demonstrated sero-
conversion of each of the patients, thus confirming their dengue
status. Of the 69 patients, 37 (53.3%) had DENV1 infections, 4
(5.8%) had DENV2, and 28 (40.6%) had DENV3, as determined
by RT-PCR on the first collection samples [34]. Of the 69 PCR-
positive patients from suite B samples, there were 33 primary
infections and 36 secondary infections. A primary dengue infection
was characterized by first collection serum (first 72 h) being
positive for DENV PCR but PanBio Indirect IgG ELISA negative.
The absence of DENV-specific IgG in the acute phase of a dengue
infection is indicative of primary dengue infection [35–37]. A
secondary dengue infection was characterized by the first
collection sample being concurrently positive for DENV PCR
and IgG. These samples were collected through a research project
(EDEN) from April 2005 to December 2006 [34] and were used
for evaluation of the established ACA-ELISA protocol.
The third suite (C), serving as a specificity test of the ACA-
ELISA, comprised three consecutive collections of saliva and sera
from 75 DENV PCR-negative febrile patients (EDEN). Collected
in the same manner as suite B, they were DENV RT-PCR
negative patients, and IgM tests revealed no sero-conversion
among all 75 cases.
Saliva Collection
Oracol saliva collection swab (Malvern Medical Development
Lid, UK) was used for saliva collection. A standardized saliva
collection protocol was used such that active saliva secretion was
obtained. Patients were instructed to swab in a scrubbing manner
their inner upper and lower cheeks 10 times each on both sides
and place the swab under their tongues for 1 min. Saliva samples,
together with blood, were transported on ice, processed within the
same day of collection, and stored at 280uC until testing.
Ethics Statement
Use of samples in suite A was approved by NEA’s Bioethics
Committee (IRB004.1). Use of samples in suites B and C was
approved by the National Healthcare Group Internal Review
Board (DSRB B/05/013). Written informed consent was obtained
from all participants.
Dengue Antigen
DENV cell culture lysate antigens used in ACA-ELISA were
prepared using a DENV 2 strain (SS194Y02) of the Cosmopolitan
genotype, isolated from a dengue patient locally, according to the
method previously described [38], and viral titre was determined
via plague assay [39]. A single batch of cell lysate was prepared
and utilized for this entire study.
ACA-ELISA
Checkerboard dilution was performed using anti-DENV IgA
positive and negative samples from suite A as reference to optimize
the ACA-ELISA for serum and saliva usage. In brief, the 96-well
plate maxisorp plates (Nunc, Denmark) were coated with 100 ml/
well of pan-DENV monoclonal antibodies (Mab; 1.15 mg/ml;
Immunology Consultants Laboratory, USA) diluted at 1:500 in
sodium bicarbonate (pH 9.5) and incubated either overnight at
4uCo r1ha t3 7 uC. After blocking the plate with dilutent buffer
(5% skim milk containing 0.05% Tween-20), virus lysate
(2.14610
6 pfu/ml) in diluent buffer was added to each well and
incubated at 37uC for 1 h. The plate was then washed six times
using washing buffer (1X PBS-0.05% Tween-20). Either 100 mlo f
test serum at 1:100 in diluent buffer or 100 ml of saliva at 1:5
dilution was added to each well. In each plate, two positive
Author Summary
The importance of laboratory diagnosis of dengue cannot
be undermined. In recent years, many dengue diagnostic
tools have become available for various stages of the
disease, but the one limitation is that they require blood as
a specimen for testing. In many incidences, phlebotomy in
needle-phobic febrile individuals, especially children, can
be challenging, and the tendency to forgo a dengue blood
test is high. To circumvent this, we decided to work toward
a saliva-based assay (antigen-capture anti-DENV IgA ELISA,
ACA-ELISA) that has the necessary sensitivity and specific-
ity to detect dengue early. Overall sensitivity of the ACA-
ELISA, when tested on saliva collected from dengue-
confirmed patients (EDEN study) at three time points, was
70% in the first 3 days after fever onset and 93% between
4 to 8 days after fever onset. In patients with secondary
dengue infections, salivary IgA was detected on the first
day of fever onset in all the dengue confirmed patients.
This demonstrates the utility of saliva in the ACA-ELISA for
early dengue diagnostics. This technique is easy to
perform, cost effective, and is especially useful in dengue
endemic countries.
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saliva), and one plate control (no sera or saliva added) were
included. The two positive controls were either two anti-DENV
IgA positive sera (titre of 1:256) or two anti-DENV IgA positive
saliva samples (titre 1:10). After 1 h of incubation at 37uC, the
plate was washed again six times, and 100 ml of 1:4000 rabbit anti-
human IgA conjugated with horse-radish peroxidase (HRP; Dako,
Denmark) was added to each well and then incubated for 30 min
at 37uC. Following incubation, the plate was then washed again six
times, and 100 ml of tetra-methyl-bencidine (TMB; Sigma, USA)
was added to each well and incubated for 5 min at room
temperature. Further color development was stopped using 100 ml
0.5 M sulphuric acid, and absorbance was measured at 450 nm
against a reference filter at 620 nm. The same batch of controls,
reagents, and dengue lysate was used for this entire study. All IgA
assays for evaluation of the protocol were performed by a single
analyst within a day, without masking the results of the reference
tests. Interval between sample collection and testing ranged from
1 mo to 1 y, during which samples were kept frozen at 280uC.
PCR, IgM, and IgG Assays
All IgM and IgG assays were performed using PanBio IgM
Capture ELISA and PanBio Indirect IgG ELISA. IgM, IgG
assays, and RT-PCR (7) were conducted by five trained personnel
of the EHI Diagnostics Unit, licensed by the Ministry of Health.
While PCR tests were performed within a day of collection of
samples, antibody tests on sera and saliva were performed either
on the same day or within 1 mo, during which samples were
frozen at 280uC.
Data Analysis
Data analysis, including calculations of correlation coefficients
and standard error of proportion, was carried out using Microsoft
Excel 2002 and Statistical Package for Social Sciences (SPSS) 17.0.
Sensitivity and its 95% confidence intervals were provided as
estimates of the effectiveness of the in-house ACA-ELISA.
Standard error of proportion was calculated using the formula !
[p(12p)/n].
Results
Cutoff Point for IgA Assay
The cutoff point of saliva IgA assays was determined with suite
A of saliva samples from healthy volunteers. Mean 6 standard
deviation optical density (OD) values of the negative controls were
determined. A sample was considered negative when the OD
value was less than the mean value for the negative control plus
two standard deviations, equivocal when the OD value exceeded
the mean value for the negative control plus 2 standard deviations
but less than 3 standard deviations and considered positive when
the OD value is above 3 standard deviations.
ACA ELISA and IgM ELISA on Saliva Samples
Suite B saliva and serum samples, consisting of three
consecutive collections from each dengue-confirmed patient, were
assayed for anti-DENV IgA using ACA-ELISA. All the serum
samples were also tested with PanBio Capture IgM ELISA. Serum
and salivary anti-DENV IgA levels showed good correlation
(Pearson’s r=0.69; p,0.001). Figure 1 shows the sensitivities of
ACA-ELISA on saliva and sera, compared to IgM Capture ELISA
on sera. ACA-ELISA on saliva had an overall sensitivity of 70% in
the first 3 d after fever onset and subsequently rose to over 90%
between 3 and 8 d after fever onset. The same technique on sera
gave similar results. More interestingly, the sensitivity of ACA-
ELISA in saliva was higher than that of IgM Capture ELISA on
sera, which detected only 10% of the dengue-confirmed patients
after 1 to 3 d of fever, and only rose to around 90% after day 6 of
fever. The specificity of the ACA-ELISA test was also found to be
high at 97%. Among the 75 DENV-negative patients in suite C,
only one patient tested positive, at day 7 and 27, respectively.
ACA-ELISA in Primary and Secondary Dengue Infection
The data of the ACA-ELISA were further analyzed with respect
to primary (n=33) and secondary (n=36) infections. The
sensitivity of the technique is detailed in Figure 2A (primary
infection) and 2B (secondary infection). Among the 33 primary
cases, the sensitivity of ACA-ELISA on saliva was 36% in the first
3 d and rose to 86% in the second collection (3 to 5 d). The
number of samples collected during 6 to 8 d was small.
Nevertheless, the results showed that at the early phase of the
disease, the sensitivity of ACA-ELISA on saliva was clearly higher
than those of ACA-ELISA and IgM Capture on sera (15% and
6% in the first 3 d after fever onset, respectively). Interestingly,
ACA-ELISA tested on the saliva and sera of 36 secondary cases
yielded sensitivities of 100% and 94%, respectively, in the first 3 d
of fever and continued to allow detection at this high rate in
second and third collection (3 to 34 d). In contrast, IgM Capture
ELISA on sera of secondary cases gave a detection sensitivity of
14% in the first 3 d and rose to 88% only by day 6.
Discussion
This study has demonstrated the potential use of saliva for early
dengue diagnostics. The sensitivity of ACA-ELISA was 70% to
92% within the first 8 d from onset of fever. Data from our
diagnostic unit have revealed that dengue patients in local settings
visit the primary health care physicians at an average of 3.5 d from
onset of fever [13]. Ninety-five percent of the patients would visit
their doctors within 0.95 to 6.03 d after fever onset. Under this
setting, we have found that our in-house RT-PCR offers 72.5%
specificity and the most sensitive commercial NS1 assay offers
81.7% [40]. Therefore, ACA-ELISA on saliva is comparable to
these early diagnosis tests and offers the additional advantages of
non-intrusive sampling and easy cost-effective laboratory proce-
dures.
It is not surprising that among the secondary dengue infections,
IgA was detected in both the saliva and sera of all individuals as
early as day 1 after fever onset, while detection in primary cases
was delayed. This is due to the presence of IgA memory cells from
the previous dengue infection that was triggered by the secondary
DENV exposure—not unlike the early IgG responses in secondary
dengue cases. This has also been observed in previous studies
[15,25,41,42]. Due to the difference in sensitivity between primary
and secondary cases, the sensitivity of the ACA-ELISA in a
population will be highly dependent on the proportion of
secondary cases in the cohort. About 50% of all dengue cases in
Singapore are secondary [34]. Under this circumstance, we
demonstrated about 70% sensitivity in the first 3 d of fever. In a
population with a higher rate of secondary cases, the sensitivity
could potentially be higher.
There are two possible explanations to the early detection of
IgA even in primary cases. Firstly, inaccuracy in reporting of the
onset dates, due to insensitivity to mild fever or bias in recalls, may
contribute to the situation. Secondly, intrinsic incubation periods
and response time vary among individuals. Dengue patients are
infected 2 to 14 d before fever onset, a period which may have
allowed IgA (and IgM) production in some individuals. Early
detection of IgM for some individuals is also evident for dengue
Use of Saliva for Early Dengue Diagnosis
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phases of dengue, IgM and IgA are present in very low levels, and
time of detection lies in the sensitivity of the technique used.
Previous studies, using AAC-ELISA, reported low sensitivities
when using salivary IgA, in contrast to our findings [15,24,25,45].
Two strategies were designed in this study to overcome the
limitation seen in previous studies. Firstly, saliva collection
protocol in this study was designed to allow for the collection of
actively secreted saliva. Previous studies on DENV-specific IgA in
saliva used passively secreted saliva in their evaluation. Prior to this
study, a comparison of the two saliva collection protocols had
revealed that, in the same individuals, actively collected saliva
yielded higher levels of DENV-specific IgA than passively collected
ones (unpublished data, Yap G). Secondly, ACA-ELISA was
designed to eliminate binding competition from high levels of non-
specific IgA that are normally present in mucosal secretions to
protect one from infectious diseases. A previously published
technique, AAC-ELISA, captured all IgA in the first step, followed
by subsequent differentiation of DENV-specific IgA from the pool
of IgAs. In the event of a dengue infection, anti-DENV IgA may
represent only a small proportion of IgA in saliva. The low
detection rate of anti-DENV IgA could be due to preexisting non-
DENV-specific IgA out-competing anti-DENV IgA. To circum-
vent the limitation, ACA-ELISA was designed to capture all anti-
DENV antibodies in its first step, followed by detection of anti-
DENV IgA. In the early phase of a primary dengue infection,
DENV-specific IgM and IgG are present in low levels, and
coupled with the enrichment of IgA in saliva, the approach is
expected to increase the detection sensitivity. The high sensitivity
of the technique could also explain the observations that in the
early phases of the disease in primary cases, DENV IgA could be
detected earlier than DENV IgM, appearing to go against classical
immunology. The capture IgM ELISA used in this study, like the
AAC-ELISA, was expected to pick up only elevated levels of
DENV IgM. The difference thus lies on the sensitivity of the
techniques used. The slightly higher sensitivity in saliva compared
to that in serum is likely due to the dimeric structure of the
secretory IgA, which could increase the amplification of signal
output from the ELISA.
Even though the antigen used in ACA-ELISA of this study was
DENV2 and not a tetravalent antigen, the ACA-ELISA is effective
in detecting IgA illicited by the three serotypes circulating in
Singapore during the study period, as DENV IgA, like IgM, is
cross-reactive with all four serotypes [46]. This is supported by a
study that demonstrated no significant differences in the sensitivity
of ACA-ELISA when DENV2 is replaced by a tetravlent antigen
(unpublished data, Yap G). A multi-country study is ongoing to
evaluate the test in various epidemiology settings, particularly to
establish its performance in settings with other circulating DENV
genotypes and other diseases that illicit cross-reacting antibodies,
Figure 1. Sensitivity of ACA-ELISA assay compared with Capture IgM ELISA. Overall sensitivity of ACA-ELISA in saliva and sera and Capture-
IgM ELISA in sera indicated the reliability of ACA-ELISA (saliva) in picking up 7 times more DENV patients compared to Capture-IgM ELISA (sera) in the
first 3 d after fever onset. The error bars showed 1 standard of deviation of the proportion for each value.
doi:10.1371/journal.pntd.0001046.g001
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specificity can be circumvented using recombinant antigen specific
to DENV.
This study suggests the potential of the saliva ACA-ELISA for
dengue diagnosis. It eliminates the need to collect blood from
dengue-suspected patients, is painless, is non-intrusive, and
reduces the risk of needle stick injury. Moreover, the ELISA-
based technique is simple and cost effective. Patients, especially the
very young and the old, will be more willing to undergo a dengue
test. Together, these benefits can potentially improve surveillance
and early detection of cases, which in turn can translate to prompt
dengue control effort. Due to its high sensitivity among secondary
dengue infections, this technique could be very useful in highly
endemic areas where the majority of the dengue cases are
secondary.
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